These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 33285270)
1. Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study. Van Limbergen EJ; Hoeben A; Lieverse RIY; Houben R; Overhof C; Postma A; Zindler J; Verhelst F; Dubois LJ; De Ruysscher D; Troost EGC; Lambin P Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1421-1430. PubMed ID: 33285270 [TBL] [Abstract][Full Text] [Related]
2. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. Lieverse RIY; Van Limbergen EJ; Oberije CJG; Troost EGC; Hadrup SR; Dingemans AC; Hendriks LEL; Eckert F; Hiley C; Dooms C; Lievens Y; de Jong MC; Bussink J; Geets X; Valentini V; Elia G; Neri D; Billiet C; Abdollahi A; Pasquier D; Boisselier P; Yaromina A; De Ruysscher D; Dubois LJ; Lambin P BMC Cancer; 2020 Jun; 20(1):557. PubMed ID: 32539805 [TBL] [Abstract][Full Text] [Related]
3. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Eigentler TK; Weide B; de Braud F; Spitaleri G; Romanini A; Pflugfelder A; González-Iglesias R; Tasciotti A; Giovannoni L; Schwager K; Lovato V; Kaspar M; Trachsel E; Menssen HD; Neri D; Garbe C Clin Cancer Res; 2011 Dec; 17(24):7732-42. PubMed ID: 22028492 [TBL] [Abstract][Full Text] [Related]
4. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071 [TBL] [Abstract][Full Text] [Related]
5. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Danielli R; Patuzzo R; Di Giacomo AM; Gallino G; Maurichi A; Di Florio A; Cutaia O; Lazzeri A; Fazio C; Miracco C; Giovannoni L; Elia G; Neri D; Maio M; Santinami M Cancer Immunol Immunother; 2015 Aug; 64(8):999-1009. PubMed ID: 25971540 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS). Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288 [TBL] [Abstract][Full Text] [Related]
7. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Johannsen M; Spitaleri G; Curigliano G; Roigas J; Weikert S; Kempkensteffen C; Roemer A; Kloeters C; Rogalla P; Pecher G; Miller K; Berndt A; Kosmehl H; Trachsel E; Kaspar M; Lovato V; González-Iglesias R; Giovannoni L; Menssen HD; Neri D; de Braud F Eur J Cancer; 2010 Nov; 46(16):2926-35. PubMed ID: 20797845 [TBL] [Abstract][Full Text] [Related]
8. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts. Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958 [TBL] [Abstract][Full Text] [Related]
9. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial. Levy A; Massard C; Soria JC; Deutsch E Eur J Cancer; 2016 Nov; 68():156-162. PubMed ID: 27764686 [TBL] [Abstract][Full Text] [Related]
11. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon. Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820 [TBL] [Abstract][Full Text] [Related]
12. Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. Sundahl N; Seremet T; Van Dorpe J; Neyns B; Ferdinande L; Meireson A; Brochez L; Kruse V; Ost P Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):828-835. PubMed ID: 30951807 [TBL] [Abstract][Full Text] [Related]
13. 30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease. Osti MF; Agolli L; Valeriani M; Reverberi C; Bracci S; Marinelli L; De Sanctis V; Cortesi E; Martelli M; De Dominicis C; Minniti G; Nicosia L Lung Cancer; 2018 Aug; 122():165-170. PubMed ID: 30032826 [TBL] [Abstract][Full Text] [Related]
14. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. van den Heuvel MM; Verheij M; Boshuizen R; Belderbos J; Dingemans AM; De Ruysscher D; Laurent J; Tighe R; Haanen J; Quaratino S J Transl Med; 2015 Jan; 13():32. PubMed ID: 25622640 [TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma. Curti B; Crittenden M; Seung SK; Fountain CB; Payne R; Chang S; Fleser J; Phillips K; Malkasian I; Dobrunick LB; Urba WJ J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32467299 [TBL] [Abstract][Full Text] [Related]
16. The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. Rekers NH; Olivo Pimentel V; Yaromina A; Lieuwes NG; Biemans R; Zegers CML; Germeraad WTV; Van Limbergen EJ; Neri D; Dubois LJ; Lambin P Oncoimmunology; 2018; 7(4):e1414119. PubMed ID: 29632732 [TBL] [Abstract][Full Text] [Related]